The Pharmacology and Therapeutic Use of Dabigatran Etexilate

Coadministration of Dabigatran Etexilate and Atorvastatin

(2013) Joachim Stangier et al.   American Journal of Cardiovascular Drugs

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) James V. Freeman et al.   ANNALS OF INTERNAL MEDICINE

Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation

(2011) Shimoli V. Shah et al.   CIRCULATION

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

(2011) John W. Eikelboom et al.   CIRCULATION

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation

(2011) Rangadham Nagarakanti et al.   CIRCULATION

2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)

(2011) L. Samuel Wann et al.   CIRCULATION

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

(2011) Elise S. Eerenberg et al.   CIRCULATION

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA

(2011) M. Wieloch et al.   EUROPEAN HEART JOURNAL

DABIGATRAN ANTICOAGULANT ACTIVITY IS NEUTRALIZED BY AN ANTIBODY SELECTIVE TO DABIGATRAN IN IN VITRO AND IN VIVO MODELS

(2011) Joanne van Ryn et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran

(2011) B. Nhi Beasley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness

(2011) Michael P Gulseth et al.   PHARMACOTHERAPY

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective

(2011) Anuraag Kansal et al.   THROMBOSIS AND HAEMOSTASIS

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

(2011) Ola Dahl et al.   THROMBOSIS AND HAEMOSTASIS

Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review

(2010) Isla M. Ogilvie et al.   AMERICAN JOURNAL OF MEDICINE

Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation

(2010) Michael D. Ezekowitz et al.   CIRCULATION

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPEAN HEART JOURNAL

2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline)

(2010) L. Samuel Wann et al.   HEART RHYTHM

Direct and indirect costs of management of long-term warfarin therapy in Canada

(2010) S. SCHULMAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation

(2010) L. JUNGBAUER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

(2010) Lars Wallentin et al.   LANCET

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

(2010) Hans-Christoph Diener et al.   LANCET NEUROLOGY

Newly Identified Events in the RE-LY Trial

(2010) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults

(2010) Michelle M. Kim et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

(2009) Michael D. Ezekowitz et al.   AMERICAN HEART JOURNAL

Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: A meta-analysis

(2009) D. A. Cios et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor

(2009) Joachim Stangier et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antithrombotic Therapy in Atrial Fibrillation

(2008) Daniel E. Singer et al.   CHEST

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate

(2008) Joachim Stangier   CLINICAL PHARMACOKINETICS

Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery

(2008)   JOURNAL OF ARTHROPLASTY

Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment

(2008) Joachim Stangier et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases

(2008) Brooke E Baetz et al.   PHARMACOTHERAPY